¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"positive focal length"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • positive pressure ventilation
    ¾ç¾Ðȯ±â(¹ý)
  • positive reinforcement
    ±àÁ¤°­È­
  • positive schizophrenia
    ¾ç¼ºÁ¤½ÅºÐ¿­º´
  • positive scotoma
    ¾ç¼º¾ÏÁ¡, ÀνľÏÁ¡
  • positive sign
    È®Á¤Â¡ÈÄ, ¾ç¼ºÂ¡ÈÄ
  • positive strand RNA
    ¾ç¼º°¡´ÚRNA
  • positive symptom
    ¾ç¼ºÁõ»ó
  • positive transference
    ±àÁ¤ÀûÀüÀÌ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • positive phase
    ¾ç¼º»ó
  • positive placebo
    (¢¡active placebo) ¾ç¼º¼ÓÀÓ¾à
  • positive pressure
    ¾ç¾Ð, Á¤¾Ð
  • positive reinforcement
    ±àÁ¤°­È­
  • positive schizophrenia
    ¾ç¼ºÁ¤½ÅºÐ¿­º´
  • positive scotoma
    ¾ç¼º¾ÏÁ¡, ÀνľÏÁ¡
  • positive soap
    ¾ç¼ººñ´©
  • positive symptom
    ¾ç¼ºÁõ»ó
  • positive transference
    ±àÁ¤Àü´Þ
  • positive trophotropism
    ¿µ¾çÇ⼺
  • positive and negative syndrome
    ¾ç¼ºÀ½¼ºÁõÈıº
  • positive end-expiratory pressure
    ³¯¼û³¡¾ç¾Ð, È£±â¸»¾ç¾Ð
  • positive predictive value
    ¾ç¼º¿¹ÃøÄ¡
  • positive strand RNA
    ¾ç¼º°¡´Ú¾Ë¿£¿¡ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • positive inotropy
    ¼öÃà·ÂÁõ°¡.(¾à¸®)(½É)¼öÃàÇ×Áø(ÀÛ¿ë).
  • positive ion
    ¾ç(åÕ)ÀÌ¿Â.
  • positive leukotaxis
    ¹éÇ÷±¸ÃßÇ⼺(ÛÜúìϹõÙú¾àõ)
  • positive negative pressure respiration
    ¾çÀ½¾ÐÈ£Èí(¹ý)(åÕëääâû¼ýåÛö), ¾ç À½¾Ðȯ±â(¹ý)(¡­üµÑ¨Ûö).
  • positive negative pressure ventilation
    ¾çÀ½¾ÐÈ£Èí(¹ý), ¾çÀ½¾Ðȯ±â(¹ý).
  • positive nitrogen balance
    ¾ç¼ºÁú¼ÒÆòÇü.
  • positive phase
    ¾ç¼º»ó(åÕàõßÓ).
  • positive phototaxis
    ¾ç(¼º)ÁÖ±¤¼º.
  • positive placebo =active p.
    ¾ç¼ºÇö󼼺¸, Ç¥Áؾà(øöñÞå·).
  • positive placebo response
    Çö󼼺¸Ä¡·á È¿°ú.
  • positive pole
    ¾ç±Ø(åÕп).
  • positive predictive value (PPV)
    ¾ç¼º ¿¹ÃøÄ¡
  • positive pressure
    ¾ç¾Ð(åÕäâ), Á¤¾Ð(ïáäâ).
  • positive pressure breathing
    ¾ç¾ÐÈ£Èí(¹ý).
  • positive pressure ventilation
    ¾ç¾Ðȯ±â(¹ý).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • focal line
    ÃÊÁ¡¼±(õ¥ïÇàÊ).
  • focal mucinosis
    ±¹¼ÒÁ¡¾×Áõ
  • focal necrosis
    ±¹¼Ò±«»ç
  • focal nephritis
    ÃÊÁ¡¼º ½Å¿°.
  • focal plane
    Ãʸé
  • focal point
    ÃÊÁ¡
  • focal segmental glomerulonephritis
    ÃÊÁ¡¼º ºÐÀý(¼º) »ç±¸Ã¼½Å¿°
  • focal segmental glomerulosclerosis; FSGS
    ±¹¼Ò¼ººÐÀý¼º»ç±¸Ã¼°æÈ­(Áõ)
  • focal spot
    ±¹¼Ò ÃÊÁ¡
  • focal spot
    ÃÊÁ¡
  • focal zone
    ÃÊÁ¡ ¿µ¿ª
  • glomerulonephritis,focal embolic
    ÃÊÁ¡¼º »öÀü¼º
  • glomerulonephritis,focal proliferative
    ÃÊÁ¡¼º Áõ½Ä¼º
  • glomerulosclerosis,focal segmental
    ÃÊÁ¡¼º ºÐÀý¼º
  • infection, oral focal
    ±¸°­º´¼Ò°¨¿°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
FGS fibrogastroscopy; focal glomerular sclerosis
FIA fistula in ano; fluorescent immunoassay; focal immunoassay; Freund incomplete adjuvant
FMC family medicine center; flight medicine clinic; focal macular choroidopathy; foundation for medical ...
FNH focal nodular hyperplasia
FOCAL formula calculation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
BCL Basic Cycle Length
CRL Crown rump length
CHL Crown-heel length
CL Cycle Length
ETL echo train length
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • positive reinforcement
    ±àÁ¤Àû °­È­, ±àÁ¤Àû °­È­¹ý, ¾ç¼º °­È­
  • positive scotoma
    ½Ç¼º ¾ÏÁ¡
    ½Ã¾ß¿¡¼­ ¾îµÎ¿î Á¡À¸·Î ³ªÅ¸³ª´Â °÷.
  • positive skin test
    ¾ç¼º ÇǺνÃÇè
  • subepithelial PAS-positive lipoglycoprotein
    »óÇÇÇÏ PAS ¾ç¼º Áö¹æ ´ç ´Ü¹é
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
focal motor seizure A simple partial seizure with localised motor activity.
(05 Mar 2000)
focal necrosis Occurrence of numerous, relatively small or tiny, fairly well-circumscribed, usually spheroidal portions of tissue that manifest coagulative, caseous, or gummatous necrosis and are characteristically associated with agents that are haematogenously disseminated; frequently observed only in histologic sections, but the foci may be as large as 1 to 3 mm and macroscopically visible; arbitrarily, foci larger than that are usually not termed focal necrosis.
(05 Mar 2000)
focal nephritis Glomerulonephritis affecting a small proportion of renal glomeruli which commonly presents with haematuria and may be associated with acute upper respiratory infection in young males, not usually due to streptococci; associated with IgA deposits in the glomerular mesangium and may also be associated with systemic disease, as in Henoch-Schonlein purpura.
Synonym: Berger's disease, Berger's focal glomerulonephritis, focal nephritis, IgA nephropathy.
(05 Mar 2000)
focal nodular hyperplasia <radiology> Focal nodules of normal hepatocytes, Kuppfer cells and bile ducts, F more than M, rare, benign, multiple in 20%, haemorrhage (most common complication) in only 2-3% (unlike hepatic adenoma), stellate fibrous septae (stellate scar), NM: normal or increased uptake on HIDA and sulfur colloid
(12 Dec 1998)
focal point Location of an organism, for fish, usually the position of the snout. Habitat measurements made at that position (depth, water velocity, etc.) are focal point measurements.
(09 Oct 1997)
focal reaction A reaction which occurs at the point of entrance of an infecting organism or of an injection, as in the Arthus phenomenon.
Synonym: local reaction.
(05 Mar 2000)
focal sclerosing glomerulopathy Focal, segmental glomerulosclerosis reported in adults and children with normal serum complement, progressing to chronic glomerulonephritis.
(05 Mar 2000)
focal sclerosis <neurology> Neurodegenerative disease characterised by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in 3rd or 4th decade with intermittent progression over an extended period. Cause still uncertain.
(18 Nov 1997)
focal sclerosis with hyalinosis <nephrology> A kidney disorder that results in fibrosis and scarring in the kidney glomerulus. The cause is unknown but some cases can result from reflux nephropathy. The clinical manifestation of this kidney disorder is nephrotic syndrome.
Symptoms include weight gain, swelling, hypertension and foamy urine. High blood cholesterol and triglyceride levels are also seen with this disorder. Treatment has included the use of corticosteroids and immunosuppressives. Antihypertensive agents and diuretics may also be necessary. Over one-half will develop chronic renal failure within 10 years of diagnosis.
(27 Sep 1997)
focal segmental glomerulosclerosis <nephrology> A kidney disorder that results in fibrosis and scarring in the kidney glomerulus. The cause is unknown but some cases can result from reflux nephropathy. The clinical manifestation of this kidney disorder is nephrotic syndrome.
Symptoms include weight gain, swelling, hypertension and foamy urine. High blood cholesterol and triglyceride levels are also seen with this disorder. Treatment has included the use of corticosteroids and immunosuppressives. Antihypertensive agents and diuretics may also be necessary. Over one-half will develop chronic renal failure within 10 years of diagnosis.
(27 Sep 1997)
focal seizure <neurology> A brief temporary alteration in movement, sensation or autonomic nerve function caused by abnormal electrical activity in a localised area of the brain.
Focal seizures (i.e. Partial or Jacksonian seizures) usually cause no change in awareness or alertness. An example of a focal (partial) seizure would be rhythmic muscle contractions in one area of the body: lip smacking, mouth movements, drooling, head turning, eye movements or seemingly purposeful movements (for example picking at clothes).
Other presentations may be strictly sensory with abnormal numbness, tingling or a crawling sensation to the skin. More unusual symptoms include changes in speech, thought, personality, mood, sensation of deja vu or hallucinations.
(05 Jan 1998)
focal spot The site of bombardment by electrons and emission of X-rays from the anode of an X-ray tube.
See: focal spot size.
(05 Mar 2000)
focal spot size The measured size of a focal spot, a function of its actual size and the angulation of the anode surface.
See: focal spot.
(05 Mar 2000)
CD4-positive T-lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the t4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes, which includes both the helper-inducer (T-lymphocytes, helper-inducer) and suppressor-inducer (T-lymphocytes, suppressor-inducer) T-cells.
(12 Dec 1998)
CD8-positive T-lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in MHC class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-lymphocytes, cytotoxic) and suppressor T-lymphocytes (T-lymphocytes, suppressor-effector).
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á